journal article·2025-04-22Open access

Nanocarrier Drug Release and Blood-Brain Barrier Penetration at Post-Stroke Microthrombi Monitored by Real-Time Förster Resonance Energy Transfer

Igor Khalin, Nagappanpillai Adarsh, Martina Schifferer, Antonia Wehn, Valeria J. Boide-Trujillo, Uta Mamrak, Joshua Shrouder, Thomas Misgeld, Severin Filser, Andrey S. Klymchenko, Nikolaus Plesnila

ACS Nano· Volume 19· Issue 15

Abstract

Nanotechnology holds great promise for improving the delivery of therapeutics to the brain. However, current approaches often operate at the organ or tissue level and are limited by the lack of tools to dynamically monitor cargo delivery in vivo. We have developed highly fluorescent lipid nanodroplets (LNDs) that enable tracking of nanocarrier behavior at the subcellular level while also carrying a Förster resonance energy transfer (FRET)-based drug delivery detection system (FedEcs) capable of monitoring cargo release in vivo. Using two-photon microscopy, we demonstrate that circulating LNDs in naïve mouse brain vasculature exhibit 3D real-time FRET changes, showing size-dependent stability over 2 h in blood circulation. Further, in the Nanostroke model, dynamic intravital two-photon imaging revealed that LNDs accumulated within cerebral postischemic microthrombi, where they released their cargo significantly faster than in normal blood circulation. Furthermore, the blood-brain barrier (BBB) became permeable at the microclot sites thereby allowing accumulated FedEcs-LNDs to cross the BBB and deliver their cargo to the brain parenchyma. This microthrombi-associated translocation was confirmed at the ultrastructural level via volume-correlative light-electron microscopy. Consequently, FedEcs represents an advanced tool to quantitatively study the biodistribution and cargo release of nanocarriers at high resolution in real-time. By enabling us to resolve passive targeting mechanisms poststroke, specifically, accumulation, degradation, and extravasation via poststroke microthrombi, this system could significantly enhance the translational validation of nanocarriers for future treatments of brain diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Photoacoustic and Ultrasonic Imaging · Ultrasound and Hyperthermia Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute for Stroke and Dementia Research (ISD), LMU University Hospital

LMU Munich

Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), GIP Cyceron, Institute Blood and Brain @ Caen-Normandie (BB@C)

Laboratory de Biophotonique et Pharmacologie

University of Strasbourg

Department of Polymer Chemistry

Government College Attingal

German Center for Neurodegenerative Diseases (DZNE)

Munich Cluster of Systems Neurology (SyNergy)

Department of Neurosurgery

LMU University Hospital

Institute of Neuronal Cell Biology, Technical University of Munich

Core Research Facilities and Services-Light Microscope Facility

Funding

Agence Nationale de la Recherche · Deutsche Forschungsgemeinschaft · H2020 Marie Sklodowska-Curie Actions · H2020 European Research Council

References (47)

Show source-provided references
1. Steinmetz J. D. · Lancet Neurol. · 2024 · 23 · 34410.1016/S1474-4422(24)00038-3 ↗
2. 10.1016/j.jconrel.2024.05.04410.1016/j.jconrel.2024.05.044 ↗
3. 10.1002/adhm.20200128910.1002/adhm.202001289 ↗
4. 10.1039/C2SM06903B10.1039/C2SM06903B ↗
5. 10.3746/pnf.2019.24.3.22510.3746/pnf.2019.24.3.225 ↗
6. 10.1016/j.ijpharm.2009.05.01410.1016/j.ijpharm.2009.05.014 ↗
7. 10.1016/j.jconrel.2016.06.02710.1016/j.jconrel.2016.06.027 ↗
8. 10.1007/s11095-010-0309-110.1007/s11095-010-0309-1 ↗
9. 10.1039/c2ra21544f10.1039/c2ra21544f ↗
10. 10.1016/j.biomaterials.2014.02.05310.1016/j.biomaterials.2014.02.053 ↗
11. 10.1002/smll.20220030210.1002/smll.202200302 ↗
12. 10.1038/nmeth.410510.1038/nmeth.4105 ↗
13. 10.1038/s41578-020-00269-610.1038/s41578-020-00269-6 ↗
14. 10.1021/acsnano.9b0180810.1021/acsnano.9b01808 ↗
15. 10.1016/j.ijpharm.2016.04.04610.1016/j.ijpharm.2016.04.046 ↗
16. 10.1096/fj.12-22132510.1096/fj.12-221325 ↗
17. 10.1161/STR.000000000000021110.1161/STR.0000000000000211 ↗
18. 10.1161/STROKEAHA.122.03933710.1161/STROKEAHA.122.039337 ↗
19. 10.1002/smll.20210625210.1002/smll.202106252 ↗
20. 10.1002/smll.20220318410.1002/smll.202203184 ↗
21. 10.3390/pharmaceutics1410215610.3390/pharmaceutics14102156 ↗
22. 10.1038/nm.202210.1038/nm.2022 ↗
23. del Zoppo G. J. · Rev. Neurol. Dis. · 2008 · 5 · S12
24. 10.1089/neu.2015.417310.1089/neu.2015.4173 ↗
25. 10.1016/j.jconrel.2015.06.02110.1016/j.jconrel.2015.06.021 ↗
26. 10.1002/adma.20180836110.1002/adma.201808361 ↗
27. 10.1038/ncomms1567810.1038/ncomms15678 ↗
28. 10.1021/cr200085w10.1021/cr200085w ↗
29. 10.1523/JNEUROSCI.2891-16.201610.1523/JNEUROSCI.2891-16.2016 ↗
30. 10.3390/bios1112050510.3390/bios11120505 ↗
31. 10.1038/s41467-021-24323-110.1038/s41467-021-24323-1 ↗
32. 10.1126/sciadv.abd688910.1126/sciadv.abd6889 ↗
33. 10.1038/nphoton.2012.33610.1038/nphoton.2012.336 ↗
34. 10.1126/science.adm686910.1126/science.adm6869 ↗
35. 10.1038/ncomms508910.1038/ncomms5089 ↗
36. Guillen J. · J. Am. Assoc. Lab. Anim. · 2012 · 51 · 311
37. 10.1371/journal.pbio.100041210.1371/journal.pbio.1000412 ↗
38. 10.3389/fneur.2021.80765810.3389/fneur.2021.807658 ↗
39. 10.3791/5764810.3791/57648 ↗
40. 10.1038/nmeth.312510.1038/nmeth.3125 ↗
41. 10.1038/nmeth.201910.1038/nmeth.2019 ↗
42. 10.1021/acsnano.0c0150510.1021/acsnano.0c01505 ↗
43. 10.2147/IJN.S33448210.2147/IJN.S334482 ↗
44. 10.1016/j.isci.2018.07.01210.1016/j.isci.2018.07.012 ↗
45. 10.1016/j.xpro.2020.10023210.1016/j.xpro.2020.100232 ↗
46. 10.3389/fncir.2018.0008810.3389/fncir.2018.00088 ↗
47. Brito A. · 2018